Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Multiple Myeloma Research Foundation focuses on effective cancer treatment

Multiple Myeloma Research Foundation focuses on effective cancer treatment

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium's sNDA for VELCADE granted priority review by the FDA

Griffin Securities' report features stem cell hypothesis of cancer

Griffin Securities' report features stem cell hypothesis of cancer

Amgen to present its four Phase 3 clinical trial results

Amgen to present its four Phase 3 clinical trial results

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

FDA provides Orphan-Drug designation for Keryx' KRX-0401 to treat multiple myeloma

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Keryx Biopharmaceuticals receives orphan-drug designation for a multiple myeloma drug

Loyola University receives funds to renovate bone marrow transplant unit

Loyola University receives funds to renovate bone marrow transplant unit

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Results from Keryx' KRX-0401 Phase 2 study to be presented at the International Kidney Cancer Symposium

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Celldex commences dosing patients in Phase 1/2 study of its CDX-1401 vaccine candidate

Ascent Therapeutics demonstrates Pepducin efficacy

Ascent Therapeutics demonstrates Pepducin efficacy

FDA approves Supplemental New Drug Application for DOXIL

FDA approves Supplemental New Drug Application for DOXIL

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

Roche Group and ImmunoCellular Therapeutics sign research agreement regarding ICT-69 antibody

Five Clinical Research Units established

Five Clinical Research Units established

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Gloucester’s romidepsin recommended for approval by the FDA Oncologic Drug Advisory Committee

Millennium's sNDA to be reviewed by the FDA

Millennium's sNDA to be reviewed by the FDA

Boron-based molecules can be used as new pharmacophores

Boron-based molecules can be used as new pharmacophores

New technique developed for the treatment of cancer

New technique developed for the treatment of cancer

Symptomless blood disorder MGUS not a precursor of serious diseases

Symptomless blood disorder MGUS not a precursor of serious diseases

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals raises funds for the development of romidepsin

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.